KOR

e-Article

Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and ConceptsSummary
Document Type
article
Source
Cellular and Molecular Gastroenterology and Hepatology, Vol 17, Iss 3, Pp 423-438 (2024)
Subject
Primary Sclerosing Cholangitis
Microbiota
Mycobiota
Gut-Liver Axis
Pathogenesis
Diseases of the digestive system. Gastroenterology
RC799-869
Language
English
ISSN
2352-345X
Abstract
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with progressive biliary inflammation, destruction of the biliary tract, and fibrosis, resulting in liver cirrhosis and end-stage liver disease. To date, liver transplantation is the only definitive treatment option for PSC. The precise etiology of PSC remains elusive, but it is widely accepted to involve a complex interplay between genetic predisposition, immunologic dysfunction, and environmental influence. In recent years, the gut-liver axis has emerged as a crucial pathway contributing to the pathogenesis of PSC, with particular focus on the role of gut microbiota. However, the role of the fungal microbiome or mycobiome has been overlooked for years, resulting in a lack of comprehensive studies on its involvement in PSC. In this review, we clarify the present clinical and mechanistic data and concepts concerning the gut bacterial and fungal microbiota in the context of PSC. This review sheds light on the role of specific microbes and elucidates the dynamics of bacterial and fungal populations. Moreover, we discuss the latest insights into microbe-altering therapeutic approaches involving the gut-liver axis and bile acid metabolism.